Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Government Set To Relaunch Free At-Home COVID-19 Tests Program

Executive Summary

Elevated levels of the COVID-19 virus in wastewater samples have prompted the Biden-Harris administration to dust off its free testing program in preparation for the fall and winter. The US Postal Service will begin shipping the testing kits in September.

While it’s no longer considered a pandemic, COVID-19 has not gone away.

In fact, the Centers for Disease Control and Prevention reports “very high” levels of the virus in wastewater samples across the US. The CDC says it can detect traces of the virus in sewage samples even if symptoms have not been reported in that community. This data can serve as an early warning of potential spread.

In response to the spike, the Biden-Harris administration says it will relaunch a free testing program which first sent out test kits in January 2022. President Biden first announced the program in December 2021. (Also see "Biden Promises 500 Million COVID-19 Tests As Omicron Threatens To Overwhelm US Health Care System" - Medtech Insight, 21 Dec, 2021.)

The policy continued sending out additional testing kits throughout 2022 and into 2023.

Now the policy, which allows US households to order up to four free at-home tests through the Department of Health’s Administration for Strategic Preparedness and Response (ASPR) website, will ramp up again toward the end of September with the tests being shipped via US mail.

The new tests, which are designed to detect current variants of the virus, can be taken at home and provide results within 15 to 30 minutes.

“At-home tests are the future of diagnosing disease,” the department says. “Reporting your result — whether negative or positive — helps your nation learn how to use those test results effectively.” — US Department of Health

Additionally, the CDC recommends all Americans older than 6 months get an updated COVID-19 vaccine for the fall and winter to protect against more serious outcomes of infection. However, the government says the tests will work on individuals of any vaccine status.

The government further advises individuals consult the FDA website for expirations dates on all authorized tests before use, as many older COVID-19 tests have expired.

The CDC recommends those testing positive follow the latest guidelines to prevent spreading the disease.

ASPR also notes that the at-home tests are antigen tests, not polymerase chain reaction, or PCR, tests. While antigen tests produce results more quickly than PCRs, they are not as accurate.

Though positive antigen results are accurate and reliable, a single negative result does not necessarily rule out infection. Therefore, the FDA advises people experiencing COVID-19 symptoms see negative results on at least two tests 48 hours apart before considering themselves free of the disease, while people without symptoms should take at least three tests.

A single PCR test, according to the FDA, can confirm an antigen result.

In total, ASPR says the government has sent out more than 900 million tests to households across the country. Health officials have maintained that testing is essential for keeping the virus at bay.

The Department of Health also requests Americans taking the tests to report their results.

“At-home tests are the future of diagnosing disease,” the department says. “Reporting your result — whether negative or positive — helps your nation learn how to use those test results effectively.”

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT155079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel